Letter to the Editor
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 14, 2025; 31(10): 103420
Published online Mar 14, 2025. doi: 10.3748/wjg.v31.i10.103420
Treatment of intermediate-to-advanced unresectable hepatocellular carcinoma is shifting toward a multidisciplinary strategy that includes multiple modalities as needed
Ken Sato
Ken Sato, Department of Healthcare Informatics, Takasaki University of Health and Welfare, Takasaki 370-0033, Japan
Ken Sato, Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan
Author contributions: Sato K developed the overall concept and contributed to the writing and editing of the manuscript, illustrations, and review of the literature.
Conflict-of-interest statement: Ken Sato has nothing to disclose.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ken Sato, Department of Healthcare Informatics, Takasaki University of Health and Welfare, 37-1 Nakaorui-machi, Takasaki 370-0033, Japan. satoken@gunma-u.ac.jp
Received: November 19, 2024
Revised: January 31, 2025
Accepted: February 12, 2025
Published online: March 14, 2025
Processing time: 99 Days and 17.6 Hours
Core Tip

Core Tip: Many treatment approaches for intermediate-to-advanced unresectable hepatocellular carcinoma are advancing, and there is an increasing amount of evidence regarding the use of combination therapies. Although there may be limitations on combinations in some regions, there is a growing need for research on multimodal treatments, which serve as the cornerstone of personalized medicine. Based on this evidence, we believe that effective combination therapies should be sought for each patient.